（文章来源：证券日报） 证券日报网讯 2月24日，哈药股份在互动平台回答投资者提问时表示，GNC中国业务的营业收入纳入哈 药股份合并财务报表。为尽快弥补母公司亏损、早日满足分红条件，公司已于2023年度及2024年度，由 子公司及控股子公司向母公司累计分配利润4.04亿元。鉴于公司2025年年度报告尚未披露，公司后续将 严格按照《公司法》《公司章程》等相关规定，合理制定利润分配方案。公司董事会、管理层高度重视 市值维护，已制定《市值管理制度》，并将市值管理纳入高级管理人员绩效考核指标。未来公司将继续 以提升内在价值为核心，持续深耕主责主业，不断提高经营质量，切实维护股东权益。 ...

Core Viewpoint - Recently, Harbin Pharmaceutical Group Co., Ltd. (stock code: 600664) announced that its subsidiary, Harbin Pharmaceutical Group Pharmaceutical Factory, received a "Drug Supplement Application Approval Notice" from the National Medical Products Administration for injectable Cefotaxime Sodium, which has passed the consistency evaluation of generic drug quality and efficacy [1] Group 1 - The drug is indicated for infections caused by sensitive bacteria, including lower respiratory tract infections, urogenital infections, and gynecological infections [1] - As of the announcement date, there are a total of 239 production approvals for injectable Cefotaxime Sodium in China, with 37 manufacturers having passed the consistency evaluation [1] - The domestic sales revenue for the drug is projected to be 1.55 billion yuan in 2024, with 889 million yuan expected in the first three quarters of 2025 [1] Group 2 - The company has invested approximately 8.1573 million yuan in research and development for the consistency evaluation project of this drug [1]

Core Viewpoint - Harbin Pharmaceutical Group Co., Ltd. has announced that its subsidiary, Harbin Pharmaceutical Group Pharmaceutical Factory, has received approval from the National Medical Products Administration for the injection of Cefoperazone Sodium, which has passed the consistency evaluation of quality and efficacy for generic drugs [1][2]. Group 1: Drug Information - The drug, Cefoperazone Sodium for injection, is available in two specifications: 1.0g and 0.5g [1]. - It is indicated for infections caused by sensitive bacteria, including lower respiratory tract infections, urogenital infections, gynecological infections, bacteremia/sepsis, skin and soft tissue infections, abdominal infections, bone and joint infections, and central nervous system infections [2]. - As of the announcement date, there are 239 production approvals for Cefoperazone Sodium in China, with 37 manufacturers having passed the consistency evaluation [2]. - The projected annual sales for Cefoperazone Sodium in domestic hospitals for 2024 is estimated at 1.55 billion yuan, with sales of 889 million yuan recorded in the first three quarters of 2025 [2]. - The company has invested approximately 8.16 million yuan in the research and development of this drug's consistency evaluation project [2]. Group 2: Impact on the Company - The approval of the drug through the consistency evaluation will likely lead to increased support in medical insurance payments and procurement by medical institutions, enhancing the market share and competitiveness of the product [3]. - The experience gained from this evaluation will benefit the company's future efforts in conducting similar evaluations for other products [3].

Core Viewpoint - Harbin Pharmaceutical Group Co., Ltd. (哈药股份) announced that its subsidiary, Harbin Pharmaceutical Group Pharmaceutical Factory (哈药总厂), received approval from the National Medical Products Administration for the injectable Cefoperazone Sodium, indicating successful consistency evaluation of quality and efficacy for generic drugs [1]. Group 1 - The approved injectable Cefoperazone Sodium is available in two dosages: 1.0g and 0.5g, with respective notification numbers 2026B00713 and 2026B00715 [1]. - Cefoperazone Sodium is indicated for infections caused by sensitive bacteria, including lower respiratory tract infections, urogenital infections, gynecological infections, bacteremia/sepsis, skin and soft tissue infections, abdominal infections, bone and joint infections, and central nervous system infections [1].

Core Viewpoint - Harbin Pharmaceutical Group Co., Ltd. (哈药股份) has received approval from the National Medical Products Administration for its injectable Cefoperazone Sodium, indicating a successful evaluation of the drug's quality and efficacy consistency as a generic medication [1]. Group 1 - The company’s subsidiary, Harbin Pharmaceutical Group Pharmaceutical Factory, is the entity that received the approval for the injectable Cefoperazone Sodium [1]. - The approved formulations include 1.0g and 0.5g dosages, with specific notification numbers for each [1]. - Injectable Cefoperazone Sodium is indicated for various infections caused by sensitive bacteria, including lower respiratory tract infections, urogenital infections, gynecological infections, bacteremia/sepsis, skin and soft tissue infections, abdominal infections, bone and joint infections, and central nervous system infections [1].

剂型：注射剂 规格：1.0g（按 C16H17N5O7S2计）、0.5g（按 C16H17N5O7S2计） 证券代码：600664 证券简称：哈药股份 编号：2026-008 哈药集团股份有限公司 关于所属企业药品通过仿制药一致性评价的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性 陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，哈药集团股份有限公司（以下简称"公司"）所属企业哈 药集团制药总厂（以下简称"哈药总厂"）收到国家药品监督管理局 颁发的关于注射用头孢噻肟钠的《药品补充申请批准通知书》【1.0g （按 C16H17N5O7S2 计），通知书编号：2026B00713；0.5g（按 C16H17N5O7S2计），通知书编号：2026B00715】，以上药品通过仿制 药质量和疗效一致性评价。现将有关情况公告如下： 一、药品的基本情况 药品名称：注射用头孢噻肟钠 上市许可持有人：哈药集团制药总厂 原药品批准文号：国药准字 H23020948、国药准字 H23020947 审批结论：本品通过仿制药质量和疗效一致性评价。 二、药品的相关信息 注射用头孢噻肟钠适用于 ...

Core Viewpoint - The company announced that its subsidiary, Harbin Pharmaceutical Group, received approval from the National Medical Products Administration for the injectable Cefotaxime Sodium (1.0g, 0.5g), which has passed the consistency evaluation for generic drugs [1] Group 1: Product Approval and Market Impact - The approved drug is indicated for various infections, which may enhance the company's product portfolio [1] - The projected domestic sales for 2024 are estimated at 1.55 billion yuan, with 889 million yuan expected in the first three quarters of 2025 [1] - The company has invested approximately 8.1573 million yuan in research and development for this product [1] Group 2: Competitive Position and Future Prospects - Passing the consistency evaluation is expected to help expand the drug's market share and improve competitiveness [1] - The company acknowledges that drug sales are influenced by multiple factors, indicating potential uncertainties in future performance [1]

Core Viewpoint - The company has received approval for the listing application of the chemical raw material drug, Ferric Protein Succinylate, which marks a significant advancement in its raw material drug sector and supports its integrated development strategy in raw material and formulation [1][3]. Group 1: Drug Approval Details - The chemical raw material drug approved is Ferric Protein Succinylate, with a packaging specification of 10kg/bag and registration number Y20230001210 [1]. - The approval was granted by the National Medical Products Administration, confirming that the drug meets the relevant requirements for drug registration [1]. Group 2: R&D Investment - The company has invested approximately RMB 8.34 million (about 834.23 thousand) in the research and development of the Ferric Protein Succinylate project as of the announcement date [2]. Group 3: Market Position - As of the announcement date, there are 11 companies in China with an "A" registration status for Ferric Protein Succinylate, including the company and Jichuan Pharmaceutical Group [2]. Group 4: Strategic Impact - The approval of Ferric Protein Succinylate is expected to enhance the company's control over its raw material production and enrich its product structure, aligning with its strategic goals [3].

Group 1 - Company Jianhui Information plans to acquire 38% equity in Boke Guoxin for RMB 73.71 million, increasing its stake from 32% to 70%, making Boke Guoxin a subsidiary [1] - Company Guangshengtang's innovative drug GST-HG141 for hepatitis B has completed the enrollment of 578 participants in its Phase III clinical trial [2] - Company Hongjing Optoelectronics is establishing a partnership with a target scale of RMB 290 million, contributing RMB 3 million as a limited partner [3] Group 2 - Company Hongchang Technology intends to acquire 21% equity in Liangzhi Joint, which will make it the controlling shareholder with a 51% stake [4] - Company Xiexin Integrated has not yet received any orders in the "space photovoltaic" sector, which remains in the exploratory phase [5] - Company Xianheng International plans to reduce its shareholding by up to 3%, amounting to a maximum of 12.28 million shares [6] Group 3 - Company Furuijia plans to reduce its repurchased shares by up to 2%, totaling 18.93 million shares [7] - Company Tianqimo is planning to issue shares and pay cash to acquire assets, leading to a temporary suspension of its stock [8] - Company Shuangqiang Technology's director plans to reduce his holdings by up to 0.32% [9] Group 4 - Company Bairun plans to adjust the conversion price of its bonds due to stock prices falling below 85% of the conversion price [11] - Company Dongnan Network has won an EPC project worth RMB 994 million [12] - Company Anhui Energy has appointed Xu Wengong as the new general manager following the resignation of Fang Shiqing [13] Group 5 - Company Lijun plans to invest up to USD 3 million to establish subsidiaries in Hong Kong and Peru [14] - Company Zhenghe Ecology has signed a strategic cooperation agreement with the government of Beijing's Miyun District [15] - Company First Venture has elected Guo Chuan as the chairman of its board [16] Group 6 - Company Changxin Bochuang's shareholder has terminated an agreement to transfer 14.5 million shares [17] - Company Hengrui Medicine's HR091506 tablet application has been accepted by the National Medical Products Administration [18] - Company Hengrui Medicine's SHR-1894 injection has received approval for clinical trials [20] Group 7 - Company Longshen Rongfa has obtained a medical device production license [21] - Company Western Securities reported that its new borrowings exceeded 20% of its net assets [22] - Company Rongfa Nuclear Power's subsidiary has won a project worth RMB 101 million [23] Group 8 - Company Taiji Industry's subsidiary has a pre-bid for the Huahong FAB9B project with a bid amount of RMB 3.778 billion [24] - Company Suzhou High-tech plans to increase its investment in a subsidiary by RMB 780 million through a debt-to-equity swap [26] - Company Electric Power Investment's vice president has resigned due to work changes [27] Group 9 - Company Hengwei Technology reported a 30.13% increase in net profit for 2025 [28] - Company Fangsheng Pharmaceutical's subsidiary has received a drug production license [29] - Company Pilin Bio's subsidiary has received a notice for clinical trial acceptance for a hemostatic drug [31] Group 10 - Company Zhongxin Fluorine Material has received approval for a stock issuance to specific investors [32] - Company Shanhe Intelligent expects a total transaction amount with related parties to be RMB 1.197 billion in 2026 [33] - Company Warner Pharmaceutical's partner has completed Phase I clinical trials for a new drug [34]

Core Viewpoint - Harbin Pharmaceutical Group Co., Ltd. has received the approval notice for the listing application of the chemical raw material drug, Ferric Succinate, from the National Medical Products Administration, indicating compliance with national drug review technical standards [1] Group 1: Company Developments - The approval of Ferric Succinate marks a significant advancement in the company's layout in the raw material drug sector, enabling self-control over related raw materials [1] - This approval will further solidify the company's integrated development strategy of raw materials and formulations, contributing to a richer product structure [1]